Healthcare & Life Sciences
Weekly Roundup
Weekly Brief — Healthcare & Life Sciences
Strategic Pivot: India’s "Value-Driven" Pharma Shift and Nationwide HPV Rollout
This report covers healthcare and pharmaceutical policy developments from March 23, 2026, to March 30, 2026. Brought to you by policyindex.ai, this intelligence highlights the conclusion of PharmaMed 2026, major regulatory easing for drug R&D, and the first-month progress of the universal HPV vaccination campaign.
Key Statistics
| 86.96 Crore | 1.2 Crore | ₹2.16 Lakh Crore |
|---|---|---|
| Total ABHA (Health Accounts) created as of March 2026 | Target age-14 girls for the national HPV vaccine drive | Total investment attracted via 14 PLI sectors |
Weekly Executive Summary
- PharmaMed 2026 Conclusion: The 9th edition of the flagship conference ended on March 27, signaling a formal policy shift from "volume-driven" (generics) to "value-driven" (biologics and innovation) ecosystems.
- Regulatory De-risking: MoHFW confirmed the implementation of a "dossier-based" licensing system and a "prior intimation" mechanism for R&D drugs, drastically reducing timelines for non-clinical testing.
- HPV Campaign Progress: One month into the nationwide launch, 5.03 lakh girls aged 14 …
Download Full Intelligence Brief (PDF)
Sign in to your PolicyIndex account to download the complete executive-ready PDF report including all policy exhibits, data tables, and strategic recommendations.
Log In to Download PDF Brief →